EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Applications of Nanobodies in Biological Imaging

Liangjü Sheng, Kai Sheng, Peng Lü iD

Cancer Biotherapy and Radiopharmaceuticals · 2025

DOI: 10.1089/cbr.2025.0005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Liangjü Sheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Jiangsu University, Zhenjiang, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Molecular Imaging, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nanobodies (Nbs), derived from Camelidae heavy-chain antibodies, are single-domain fragments (15 kDa) with high antigen-binding specificity, enhanced tissue penetration, and low immunogenicity. These attributes address limitations of conventional antibodies, positioning Nbs as pivotal tools for targeted molecular imaging in diagnostics and therapeutics.

Methods

Nbs are screened through phage/mRNA display or single B-cell sequencing, expressed in prokaryotic or yeast systems, and humanized via CDR grafting. Functional probes are engineered by conjugating Nbs with radionuclides (68Ga, 99mTc) or fluorophores (IRDye 800CW) for compatibility with PET, SPECT, NIRF, and ultrasound modalities.

Results

Clinical trials validated Nb efficacy: 68Ga-HER2-Nb PET/CT achieved tumor-specific uptake in HER2+ cancers (NCT04467515), while 99mTc-PD-L1-Nb enabled quantitative SPECT-guided immunotherapy in NSCLC. NIRF-Nb conjugates (e.g., 11A4-800CW) enhanced intraoperative tumor delineation in murine models. Dual-targeted ultrasound microbubbles demonstrated multi-biomarker imaging via acoustic pressure modulation.

Conclusion

Nbs advance biological imaging through superior resolution and rapid pharmacokinetics. Challenges persist in optimizing probe stability, minimizing immunogenicity, and scaling production. Future priorities include integrating multi-modal platforms, expanding applications to neurodegenerative disorders, and refining personalized diagnostic paradigms, underscoring their transformative potential in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesMolecular ImagingNeoplasmsHumansAnimalsMiceRadiopharmaceuticalsPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

VHH humanizationheavy chain variable regionmolecular imagingnanoparticlespositron emission tomographysingle-photon emission computed tomography

Substanzen

Single-Domain AntibodiesRadiopharmaceuticals

Autor:innen und Institutionen

  • School of Medicine, Jiangsu University, Zhenjiang, China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, China.

ORCID-Profile: Peng Lü

Zitieren

APA

Sheng, L., Sheng, K., & Lü, P. (2025). Applications of Nanobodies in Biological Imaging. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2025.0005

Vancouver

Sheng L, Sheng K, Lü P. Applications of Nanobodies in Biological Imaging. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2025.0005

BibTeX
@article{Sheng2025,
  author = {Sheng, Liangjü and Sheng, Kai and Lü, Peng},
  title = {Applications of Nanobodies in Biological Imaging},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2025},
  doi = {10.1089/cbr.2025.0005}
}
Kostenlos starten →